ALNY Alnylam Pharmaceuticals Inc.

+2.32  (+3%)
Previous Close 78.37
Open 78.77
Price To Book 5.11
Market Cap 8,973,345,359
Shares 111,207,651
Volume 504,297
Short Ratio
Av. Daily Volume 696,426

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Noted September 7, 2017 that Fitusiran program suspended dosing due to fatal thrombotic event. Announced December 15, 2017 that clinical hold has been released. Dosing to resume later December.
Hemophilia A and B
PDUFA date under priority review February 4, 2020.
Acute hepatic porphyrias
Phase 3 data due second half of 3Q 2019.
Inclisiran - ORION-9
Phase 1/2 data due late-2019.
ALN-HBV02 (VIR-2218))
Chronic hepatitis B virus (HBV)
Phase 3 data due late-2019.
Primary Hyperoxaluria Type 1 (PH1)
FDA Approval announced August 10, 2018.
Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR
Phase 2 trial to be initiated.
ALN-CC5 (cemdisiran)
IgA nephropathy
Phase 3 first read-out expected 2H 2019
Fitusiran (ATLAS)
Phase 3 trial enrolling - noted December 6, 2018.
ATTR amyloidosis
Phase 3 data due second half of 3Q 2019.
Inclisiran - ORION-10
Cardiovascular disease (ASCVD)
Phase 3 data to be presented at ESC September 2, 2019 at 9:22 am CET.
Inclisiran - ORION 11
Cardiovascular disease (ASCVD)
Phase 1/2 data due late-2019.
alpha-1 anti-trypsin deficiency-associated liver disease
Phase 3 top-line data due mid-2020.
Primary Hyperoxaluria Type 1
Phase 3 trial to be initiated mid-2019.
Patisiran APOLLO-B
Wild-type ATTR amyloidosis patients with cardiomyopathy
Phase 3 trial to be initiated 2H 2019.
Impaired renal function
Phase 1 dosing has commenced - noted May 31, 2019. Initial data due late-2019.
Phase 3 trial to be initiated 2H 2019.
ALN-TTRsc02 (vutrisiran) - HELIOS-B
ATTR amyloidosis with cardiomyopathy

Latest News

  1. BioBoyScout’s Online Biotech Valuation Calculators Help Small Investors See Value in Arrowhead Pharmaceuticals (ARWR)
  2. Regeneron Gets FDA Nod for Eylea Injection Prefilled Syringe
  3. Biotech Stock Roundup: Amgen's Enbrel Patent Win, AMRN's Setback & More
  4. Alnylam to Report New Clinical Results for Givosiran at the 2019 International Congress on Porphyrins and Porphyrias
  5. Alnylam Pharmaceuticals and Ironwood Pharmaceuticals Enter U.S. GI Disease Education and Promotional Agreement for Alnylam’s Givosiran in Acute Hepatic Porphyria (AHP)
  6. Ironwood Pharmaceuticals and Alnylam Pharmaceuticals Enter U.S. GI Disease Education and Promotional Agreement for Alnylam’s Givosiran in Acute Hepatic Porphyria (AHP)
  7. Alnylam Adds on Sales, Looks to Pipeline for Further Growth
  8. Edited Transcript of ALNY earnings conference call or presentation 6-Aug-19 12:00pm GMT
  9. Alnylam's (ALNY) Q2 Earnings and Revenues Miss Estimates
  10. Alnylam Pharmaceuticals Inc (ALNY) Q2 2019 Earnings Call Transcript
  11. Regeneron (REGN) Q2 Earnings Top Estimates, Eylea Sales Solid
  12. Alnylam Pharmaceuticals (ALNY) Reports Q2 Loss, Lags Revenue Estimates
  13. Alnylam Pharmaceuticals Reports Second Quarter 2019 Financial Results and Highlights Recent Period Activity
  14. The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering
  15. Alnylam Announces U.S. Food and Drug Administration (FDA) Granted Priority Review of the Givosiran New Drug Application (NDA) for the Treatment of Acute Hepatic Porphyria
  16. bluebird's (BLUE) Loss Wider Than Expected, Revenues Beat
  17. Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q2
  18. Amgen (AMGN) Catches Eye: Stock Jumps 5.7%
  19. Earnings Preview: Alnylam Pharmaceuticals (ALNY) Q2 Earnings Expected to Decline
  20. A Look At The Fair Value Of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)